Project Grant R21AI199887
Award Date 8/1/26
Completion Date 7/31/28
Dollars Obligated $435K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Notre Dame, IN 46556, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases awarded the University of Notre Dame DU Lac $158,000 on June 10, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct spatial mapping research on Pseudomonas aeruginosa biofilm organization and stress resilience. The research combines multiple spatial analytical techniques—fluorescence microscopy, polarized light microscopy, and confocal Raman microscopy—to map the localization of alkyl quinolones...
- The National Institute of Allergy and Infectious Diseases awarded the University of Notre Dame DU Lac $709,532 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct systematic research into the cytoplasmic pathway for peptidoglycan recycling in Pseudomonas aeruginosa, an antibiotic-resistant gram-negative bacterial pathogen responsible for recurrent lung infections in cystic fibrosis patients. The work addresses two specific aims. The first...
- The National Institute of Allergy and Infectious Diseases awarded the University of Notre Dame DU Lac $464,176 on April 3, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to evaluate species-specific yeast RNAi insecticides for sand fly control as vectors of leishmaniasis. The research evaluates the potential of RNAi yeast-based insecticides to control sand flies, particularly the genera Phlebotomus (Africa, Asia, Europe) and Lutzomyia (Americas), which transmit...
- The National Institute of Allergy and Infectious Diseases, part of the Department of Health and Human Services, awarded $790,946 to Indiana University Indianapolis on February 10, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate dysregulation of humoral immunity following Plasmodium infection. The research examines why Plasmodium infections fail to induce long-lasting antibody protection, unlike most other infections and vaccines. The project...
- The National Institute of Allergy and Infectious Diseases awarded the University of Notre Dame Du Lac $197,500 on June 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate how tyloxapol inhibits mycobacterial type VII secretory activity. The research addresses the molecular mechanisms by which tyloxapol, a non-ionic detergent, impairs the ESX-1 secretion system essential for mycobacterial infection. Preliminary data demonstrate that sub-critical...
- The National Institute of Allergy and Infectious Diseases awarded the University of South Florida $203,060 on April 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate the ecology and transmission dynamics of Plasmodium malariae in Cameroon. The research will assess the spatial distribution and seasonal trends of P. malariae in Bangolan, a lakeshore area in Cameroon's northwest region, through molecular surveillance conducted via repeated...
- The National Institute of Allergy and Infectious Diseases awarded the University of Notre Dame $614,655 on July 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate bladder inflammatory and immune responses to fungal catheter-associated urinary tract infections caused by Candida albicans. The research addresses a significant knowledge gap in understanding fungal catheter-associated urinary tract infections, which now represent the second leading...
- The National Institute of Allergy and Infectious Diseases (NIAID), a component of the Department of Health and Human Services National Institutes of Health, awarded the University of Notre Dame $237,000 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop monoclonal antibody-conjugated nanoparticles for targeted cytomegalovirus antiviral delivery. The project addresses limitations of current CMV therapies—ganciclovir and valganciclovir—which...
- The National Institute of Allergy and Infectious Diseases awarded Iowa State University $578,956 on July 13, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to support research on the regulation of axoneme assembly during Plasmodium falciparum gametogenesis, a study aimed at advancing malaria vaccine development. The project, designated R01AI195769, runs through June 30, 2031, with work performed in Ames, Iowa. The research addresses the mechanisms of flagellar...
- The National Institute of Allergy and Infectious Diseases awarded the University of Notre Dame $769,354 on May 22, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to elucidate spore germination machinery in Clostridioides difficile and optimize a class of antibiotics called oxadiazoles as spore germination inhibitors. The research addresses recurrent C. difficile infections, which occur in approximately 25 percent of patients and represent a significant source of...